What intravenous prostacyclin (epoprostenol or treprostinil) dosing regimen is recommended for treating pulmonary arterial hypertension?

Recommended IV Prostacyclin Dosing for Pulmonary Arterial Hypertension

For epoprostenol, start at 2 ng/kg/min and increase as tolerated; for IV treprostinil, start at 1.25 ng/kg/min (or 0.625 ng/kg/min if not tolerated), increase by 1.25 ng/kg/min weekly for the first 4 weeks, then by 2.5 ng/kg/min weekly thereafter based on clinical response. 1, 2

Epoprostenol Dosing

• Initial dose: 2 ng/kg/min via continuous IV infusion 1
• Titration: Increase as tolerated based on clinical response
• Key considerations:
  • Requires cooling and frequent reservoir changes due to chemical instability 3
  • Short half-life necessitates uninterrupted infusion
  • Has the strongest evidence for mortality benefit and hemodynamic improvement 4

IV Treprostinil Dosing

• Initial dose: 1.25 ng/kg/min via continuous IV infusion 2

  • If systemic effects are not tolerated, reduce to 0.625 ng/kg/min 2

• Titration schedule: 2

  • Weeks 1-4: Increase by 1.25 ng/kg/min per week
  • After week 4: Increase by 2.5 ng/kg/min per week
  • More frequent adjustments permitted if tolerated

• Key advantages:

  • Longer half-life and chemical stability at room temperature 5
  • No cooling required
  • Easier drug preparation 5

Special Dosing Situations

Hepatic Insufficiency

For patients with mild or moderate hepatic insufficiency on treprostinil, reduce the initial dose to 0.625 ng/kg/min 2

Transition from Epoprostenol to IV Treprostinil

When switching from epoprostenol to IV treprostinil, you must approximately double the dose to maintain equivalent clinical efficacy 5, 6. A rapid 1:1 switch protocol has been studied, but patients typically require dose escalation to 2-fold the baseline epoprostenol dose over 12 weeks to maintain clinical status 7.

Transition from Subcutaneous Treprostinil

When transitioning from subcutaneous to IV treprostinil, maintain the same dose the patient is currently receiving 2

Clinical Pitfalls and Caveats

Avoid abrupt cessation of either medication, as this can lead to rapid clinical deterioration 2. If infusion is interrupted for only a few hours, restart at the same dose; longer interruptions may require re-titration 2.

The dosing differences between epoprostenol and IV treprostinil are clinically significant—IV treprostinil maintenance doses in practice are approximately twice those of epoprostenol 6, which has direct implications for drug costs and clinical equivalence.

Target dose is individualized based on achieving improvement in WHO functional class while minimizing side effects (headache, nausea, emesis, restlessness, anxiety) 2. The goal is to shift patients from higher-risk to lower-risk phenotype with target parameters including WHO FC I-II, 6MWD >380-440m, and normalized right ventricular function 8.

Patient Selection for IV Prostacyclins

IV prostacyclin therapy should be initiated in WHO Functional Class IV patients and/or those with high-risk features as first-line therapy 8. These agents remain the most effective treatment for advanced PAH despite newer drug classes 6, with epoprostenol demonstrating the greatest improvements in hemodynamics (PAP reduction P-score 0.95) and functional capacity (6MWD improvement P-score 0.90) 4, while treprostinil shows 34% mortality reduction versus placebo 4.